



CURE

Global X S&P Biotech ETF



Invest in the cures and vaccines of today and tomorrow.

Thematic Growth – People & Demographics

FUND DETAILS

ASX Code	CURE
Bloomberg Code	CURE AU EQUITY
IRESS Code	CURE.AXW
Benchmark	S&P Biotechnology Select Industry Index
Mgt. Fee (% p.a.)*	0.45
Rebalance Frequency	Quarterly
Distribution Frequency	Annually
W-8 BEN Form Required	No

* Calculated on the Net Asset Value (NAV) of the Fund. All fees and costs are inclusive of GST. Refer to the PDS for a complete list of fees and costs.

KEY FEATURES



High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.



Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.



Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

INTRODUCING CURE

CURE offers investors exposure to US biotechnology stocks, across small-, mid- and large-capitalisation companies. CURE aims to provide investors with a return that, before fees and expenses, tracks the performance of the S&P Biotechnology Select Industry Index.

DID YOU KNOW?

- The US biotechnology industry is valued at US\$193.1bn¹. This is approximately 28.4x the size of the Australian biotechnology industry².
- It takes on average 10.5 years to bring a new drug to market³.


WHAT IS THE BIOTECHNOLOGY SUB-INDUSTRY?

Biotechnology refers to technologies that use biological processes and is a sub-industry of the healthcare sector, capturing companies that focus on research, development, manufacturing of products based on biological and genetic information. This includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a health care application.

EXAMPLES OF BIOTECHNOLOGY

- Immunotherapy treatments.
- Vaccines to treat human diseases.

Innovations from the companies in the index range from treatments for diseases such as sickle cell disease, diabetes or HIV/AIDS, detection and treatment for types of cancer or research and development into vaccines for illnesses like Zika Virus or COVID-19.





USA: THE CENTRE OF BIOTECHNOLOGY

The US Food & Drug Administration (FDA) approval process is world-renowned and any companies seeking access to distribute their products in the US market need to submit to FDA evaluation. It has set a global standard and many international companies have sought to base themselves in the US to more easily take part in the FDA approval process as well as allow themselves better distribution access to US consumers.

HOW CURE WORKS

- A minimum of 35 index constituents which are also members of the S&P Total Market Index and classified as Biotechnology sub-industry stocks.
- Companies must have a minimum market capitalisation of US\$300m and float-adjusted liquidity ratio of 50% (for existing index constituent, new constituents have higher requirements).
- Companies are weighted equally rather than by market capitalisation and rebalanced quarterly.

HOW TO USE CURE IN A PORTFOLIO

- CURE can be used to express long-term strategic views or short-term tactical views on the biotechnology sub-industry.
- It can assist in diversifying Australian portfolios across biotechnology, given the highly concentrated exposure domestically.
- As a thematic tilt towards megatrends.

For more information on Global X S&P Biotech ETF (ASX Code: CURE), please speak to Global X ETFs.

Client Services

+61 2 8311 3488 | Info@globalxetfs.com.au

[1] (IBISWorld, 2024)<https://www.ibisworld.com/united-states/market-research-reports/biotechnology-industry/#:~:text=Industry%20revenue%20has%20declined%20at,estimated%20%24193.1bn%20in%202023>.

[2] (IBISWorld, 2024)<https://www.ibisworld.com/au/market-size/biotechnology/>

[3] (N-Side, 2022)<https://lifesciences.n-side.com/blog/what-is-the-average-time-to-bring-a-drug-to-market-in-2022>

This document is issued by Global X Management (AUS) Limited ("Global X") (Australian Financial Services Licence Number 466778, ACN 150 433 828) and Global X is solely responsible for its issue. This document may not be reproduced, distributed or published by any recipient for any purpose. Under no circumstances is this document to be used or considered as an offer to sell, or a solicitation of an offer to buy, any securities, investments or other financial instruments. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS) which is available at www.globalxetfs.com.au. In respect of each retail product, Global X has prepared a target market determination (TMD) which describes the type of customers who the relevant retail product is likely to be appropriate for. The TMD also specifies distribution conditions and restrictions that will help ensure the relevant product is likely to reach customers in the target market. Each TMD is available at www.globalxetfs.com.au. The information provided in this document is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information in this document, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance. Standard & Poor's S&P Indices are trademarks of Standard & Poor's Financial Services LLC. "S&P", as used in the term S&P 500, is a trademark of Standard & Poor's Financial Services LLC ("S&P") respectively and has been licensed for use by Global X. Global X products are not sponsored, endorsed, sold or promoted by S&P, and S&P does not make any representation regarding the advisability of investing in Global X products.

Information current as at 5 December 2023.